Sector
PharmaceuticalsOpen
₹1,770.05Prev. Close
₹1,765Turnover(Lac.)
₹68.99Day's High
₹1,797Day's Low
₹1,75552 Week's High
₹2,215.2452 Week's Low
₹1,121.9Book Value
₹0Face Value
₹10Mkt Cap (₹ Cr.)
1,792.79P/E
95.59EPS
18.58Divi. Yield
031 Aug 2024
12:00 AM
AGM
Announcement Date: 31 Aug, 2024
9 May 2025
12:00 AM
Board Meeting
Agenda : Audited Result
27 Nov 2024
12:00 AM
EGM
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 9.61 | 9.61 | 9.61 | 9.61 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 106.4 | 86.64 | 67.85 | 53.8 |
Net Worth | 116.01 | 96.25 | 77.46 | 63.41 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Revenue | 79.45 | 58.04 | 50.56 | |
yoy growth (%) | 14.79 | 21.4 | ||
Raw materials | -43.44 | -30.44 | -27.18 | |
As % of sales | 54.68 | 52.44 | 53.75 | |
Employee costs | -6.05 | -3.41 | -1.88 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 9.88 | 7.46 | 6.83 | |
Depreciation | -5.26 | -2.57 | -2.42 | -1.85 |
Tax paid | -2.9 | 0.24 | -0.07 | |
Working capital | 6.55 | 5.39 | -7.9 | 17.2 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 14.79 | 21.4 | ||
Op profit growth | 8.99 | 29.86 | ||
EBIT growth | 4.45 | 29.28 | ||
Net profit growth | 14.05 | 58.42 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 362.36 | 295.71 | 227.11 | 183.84 | 116.12 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 362.36 | 295.71 | 227.11 | 183.84 | 116.12 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 6.44 | 1.36 | 0.75 | 0.76 | 0.5 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,669.8 | 93.52 | 4,00,520.99 | 2,000.46 | 0.96 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,616 | 79.48 | 1,75,574.28 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,513.8 | 25.39 | 1,22,186 | 1,485.4 | 1.06 | 4,254.47 | 397.41 |
Dr Reddys Laboratories Ltd DRREDDY | 1,321.5 | 20.61 | 1,10,263.53 | 1,200.7 | 0.61 | 5,546.3 | 345.76 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,222.5 | 57.29 | 1,09,167.44 | 474 | 0.99 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time Director
Balwant Singh.
Joint Managing Director
Varun Batra
Chairperson & M D
Rahul Batra
Independent Director
Manmohan Khanna
Independent Director
Rohit Parti
Company Sec. & Compli. Officer
Rajni Brar
Whole-time Director
Ashutosh Shukla
Village Nandpur,
Himachal Pradesh - 174101
Tel: 91-1795-236196
Website: http://www.betadrugslimited.com
Email: [email protected]
C-101 247 Park,
L B S Marg, Vikhroli West,
Mumbai-400083
Tel: 91-22-49186000
Website: www.linkintime.co.in
Email: [email protected]
Summary
Beta Drugs Limited was incorporated as a private limited company with the name Beta Drugs Private limited at Himachal Pradesh on September 21, 2005. Subsequently, the company was converted in to publi...
Read More
Reports by Beta Drugs Ltd
What is the Beta Drugs Ltd share price today?
What is the Market Cap of Beta Drugs Ltd?
What is the PE and PB ratio of Beta Drugs Ltd?
What is the 52 Week High and Low of Beta Drugs Ltd?
What is the CAGR of Beta Drugs Ltd?
What is the shareholding pattern of Beta Drugs Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.